Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan

May 7, 2026 - 19:34

Artivion, a medical device company focused on cardiac and vascular surgery, reported its financial results for the first quarter of 2026, showing a solid increase in revenue. The company also announced it has exercised its option to acquire Endospan, a move that expands its presence in the aortic repair market.

For the quarter ending March 31, 2026, Artivion recorded revenue of $116.3 million. This marks a significant jump from the $99.0 million reported in the same period last year. The growth was driven by strong sales across several product lines, including the company's core surgical grafts and stent graft systems. Management attributed the performance to increased procedure volumes and successful commercial execution in key markets.

The acquisition of Endospan is a strategic step for Artivion. Endospan specializes in endovascular solutions for complex aortic diseases. By bringing this technology in-house, Artivion aims to strengthen its portfolio of minimally invasive treatments. The deal is expected to close in the coming months, pending customary conditions.

Looking ahead, Artivion reaffirmed its full-year guidance for 2026. The company expects continued revenue growth driven by new product launches and expanding global demand for its surgical and endovascular devices. Executives expressed confidence in the company's trajectory, citing a strong pipeline and a focus on improving patient outcomes.